Bruno L Cadilha
Overview
Explore the profile of Bruno L Cadilha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1003
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lorenzini T, Cadilha B, Obeck H, Benmebarek M, Markl F, Michaelides S, et al.
Br J Cancer
. 2023 Jul;
129(4):696-705.
PMID: 37400680
Background: In many situations, the therapeutic efficacy of CAR T cells is limited due to immune suppression and poor persistence. Immunostimulatory fusion protein (IFP) constructs have been advanced as a...
2.
Markl F, Benmebarek M, Keyl J, Cadilha B, Geiger M, Karches C, et al.
J Immunother Cancer
. 2023 May;
11(5).
PMID: 37208128
Background: Melanoma is an immune sensitive disease, as demonstrated by the activity of immune check point blockade (ICB), but many patients will either not respond or relapse. More recently, tumor...
3.
Gottschlich A, Thomas M, Grunmeier R, Lesch S, Rohrbacher L, Igl V, et al.
Nat Biotechnol
. 2023 Mar;
41(11):1618-1632.
PMID: 36914885
Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment option for individuals with B cell malignancies but have yet to achieve success in treating acute myeloid...
4.
Seifert M, Benmebarek M, Briukhovetska D, Markl F, Dorr J, Cadilha B, et al.
Br J Cancer
. 2022 Oct;
127(12):2175-2185.
PMID: 36266575
Background: Chimeric antigen receptor (CAR) T cell therapy has been successfully translated to clinical practice for the treatment of B cell malignancies. The suppressive microenvironment of many malignancies is a...
5.
Holting T, Cidre-Aranaz F, Matzek D, Popper B, Jacobi S, Funk C, et al.
Mol Cancer
. 2022 Oct;
21(1):199.
PMID: 36229873
Chimeric fusion transcription factors are oncogenic hallmarks of several devastating cancer entities including pediatric sarcomas, such as Ewing sarcoma (EwS) and alveolar rhabdomyosarcoma (ARMS). Despite their exquisite specificity, these driver...
6.
Tokarew N, Gosalvez J, Nottebrock A, Briukhovestka D, Endres S, Cadilha B, et al.
Methods Cell Biol
. 2022 Feb;
167:99-122.
PMID: 35153001
Adoptive T cell therapy (ACT) is a therapeutic approach which employs genetically manipulated autologous T cells to target and eliminate a patient's malignancy. This novel therapeutic approach, when employing a...
7.
CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment
Di Pilato M, Kfuri-Rubens R, Pruessmann J, Ozga A, Messemaker M, Cadilha B, et al.
Cell
. 2021 Aug;
184(17):4512-4530.e22.
PMID: 34343496
Cytotoxic T lymphocyte (CTL) responses against tumors are maintained by stem-like memory cells that self-renew but also give rise to effector-like cells. The latter gradually lose their anti-tumor activity and...
8.
Cadilha B, Benmebarek M, Dorman K, Oner A, Lorenzini T, Obeck H, et al.
Sci Adv
. 2021 Jun;
7(24).
PMID: 34108220
CAR T cell therapy remains ineffective in solid tumors, due largely to poor infiltration and T cell suppression at the tumor site. T regulatory (T) cells suppress the immune response...
9.
Blaeschke F, Stenger D, Apfelbeck A, Cadilha B, Benmebarek M, Mahdawi J, et al.
Blood Cancer J
. 2021 Jun;
11(6):108.
PMID: 34088894
No abstract available.
10.
Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha B, et al.
Nat Biomed Eng
. 2021 Jun;
5(11):1246-1260.
PMID: 34083764
The efficacy of adoptive cell therapy for solid tumours is hampered by the poor accumulation of the transferred T cells in tumour tissue. Here, we show that forced expression of...